Third, because the low incidence of ICI-DM as an adverse effect of PD-1/PD-L1 inhibition makes it difficult to study the patient cohort at risk for developing such complications, further studies, including a large number of cases, are needed. The gene discussed is PDCD1; the disease is diabetes mellitus.